I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301.
Global Banking News-October 12, 2018-I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301
(C)2018 ENPublishing - http://www.enpublishing.co.uk
Immuno-inflammation company I-Mab Biopharma revealed on Thursday that it has dosed the first patient in China under its phase II clinical trial of TJ301 for the treatment of Ulcerative Colitis (UC), a chronic inflammatory bowel disease.
The company has initiated its phase II clinical trial of TJ301 for the treatment of ulcerative colitis (UC) at the Division of Gastroenterology, the First Affiliated Hospital of Sun Yat-sen University in Guangdong, China.
According to the company, TJ301 is a phase II, randomised, double-blind, placebo-controlled study that is being conducted in multiple sites across China, South Korea and Taiwan area to evaluate the safety and efficacy of TJ301 administered intravenously in patients with active ulcerative colitis.
TJ301, a selective IL-6 blocker, works through a novel trans-signalling mechanism without interacting with either IL-6 or IL-6R individually. This mechanism of action is unique from other anti-IL6 or anti-IL6R products that block all actions of IL-6. TJ301 is expected to have a better safety profile over the existing IL-6-based biologics, added the company.
In conjunction, the company I-Mab holds the exclusive rights to TJ301 for further development and commercialisation in Greater China and South Korea under a licensing agreement with Ferring.
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Global Banking News (GBN)|
|Date:||Oct 12, 2018|
|Previous Article:||Synthetic Biologics prices USD18m public offering of common stock, preferred stock & warrants.|
|Next Article:||Capio reports preliminary Q3 2018 results.|